Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Vitatex Inc
Profile last edited on: 10/9/2017      CAGE: 4KB71      UEI: KLSJEM5QGWS5

Business Identifier: Assays that analyze invasive circulating tumor cells in standard patient blood samples
Year Founded
2002
First Award
2003
Latest Award
2016
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

25 Health Sciences Drive Suite 220
Stony Brook, NY 11790
   (631) 444-8482
   info@vitatex.com
   www.vitatex.com
Location: Single
Congr. District: 01
County: Suffolk

Public Profile

Vitatex is focused on developing assays that analyze invasive circulating tumor cells (iCTCs) in standard patient blood samples. The company’s unique advantage stems from its patented approach that captures iCTCs directly linked to the metastatic process. Leveraging its functional Cell Adhesion Matrix (CAM) technology, Vitatex is developing proprietary diagnostic tests that can be run on blood samples collected by current standard methods in order to improve cancer treatment decisions. iCTCs captured by the Vitatex method are alive and can be cultured in the presence of panels of cancer drugs; this enables the selection of optimized treatments tailored to each patient.

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
3
Conversion Rate
60.00%
Phase I Dollars
$2,697,079
Phase II Dollars
$6,246,425
Total Awarded
$8,943,504

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2016 2 NIH $2,243,431
Project Title: IGF::OT::IGF TITLE: Vita Cap Tube to Preserve Circulating Tumor Cells in Blood
2015 1 NIH $1,952,181
Project Title: IGF OT IGF Title SBIR Phase I Vita Cap Tube to Preserve Circulating Tumor Cells in Blood Pop
2012 2 NIH $2,208,305
Project Title: Cancer Progeniyor Cell Markers
2007 2 NIH $2,362,414
Project Title: Cancer detection technology
2003 1 NIH $177,173
Project Title: Gene Expression of Viable Ovarian Cancer Cells

Key People / Management

  Wen-Tien Chen -- President and Founder

  Che Chen -- Director of Operations

  Lee Chen -- Senior Vice President, Operations

  Huan Dong -- Director, Product Research

  Casey Eitner -- Former Senior Vice President, Business Development

  Shaun Tulley -- Director, Quality Management

  Helen N Wesley

  Qiang Zhao -- Director, Medical Research

Company News

There are no news available.